Pages that link to "Q73181790"
Jump to navigation
Jump to search
The following pages link to Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer (Q73181790):
Displaying 50 items.
- Concurrent chemoradiotherapy in non-small cell lung cancer (Q24234963) (← links)
- Concurrent chemoradiotherapy in non-small cell lung cancer (Q24245635) (← links)
- Concurrent chemoradiotherapy with low dose weekly gemcitabine in stage III non-small cell lung cancer (Q24810507) (← links)
- The impact of epidermal growth factor receptor mutations on patterns of disease recurrence after chemoradiotherapy for locally advanced non-small cell lung cancer: a literature review and pooled analysis (Q26741041) (← links)
- Radio(chemo)therapy in locally advanced nonsmall cell lung cancer (Q26765355) (← links)
- Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies (Q26775388) (← links)
- Novel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancer (Q26827571) (← links)
- Concurrent systemic therapy with radiotherapy for the treatment of poor-risk patients with unresectable stage III non-small-cell lung cancer: a review of the literature (Q26851579) (← links)
- 50 Years of progress in the systemic therapy of non-small cell lung cancer (Q27014978) (← links)
- Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship (Q28278682) (← links)
- The effect of consolidation chemotherapy after concurrent chemoradiotherapy on the survival of patients with locally advanced non-small cell lung cancer: a meta-analysis (Q30239983) (← links)
- Recent developments in weekly paclitaxel therapy in lung cancer (Q30652506) (← links)
- Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: preclinical and early clinical data (Q30910296) (← links)
- Predictive factors in radiotherapy for non-small cell lung cancer: present status. (Q31857384) (← links)
- Treatment of non-small cell lung cancer with intensity-modulated radiation therapy in combination with cetuximab: the NEAR protocol (NCT00115518). (Q33242719) (← links)
- Phase II study of concurrent chemotherapy and radiotherapy for unresectable stage III non-small-cell lung cancer: long-term follow-up results. Japan Clinical Oncology Group Protocol 8902. (Q33332758) (← links)
- A 3-week schedule of gemcitabine plus cisplatin as induction chemotherapy for Stage III non-small cell lung cancer (Q33341073) (← links)
- A phase II study of continuous concurrent thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small cell lung cancer (Q33341441) (← links)
- Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung cancer (Q33344354) (← links)
- A phase II trial of concurrent chemoradiation therapy followed by consolidation chemotherapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancers (Q33357243) (← links)
- Phase Ia/Ib chemo-radiation trial of gemcitabine and dose-escalated thoracic radiation in patients with stage III A/B non-small cell lung cancer. (Q33374782) (← links)
- Toxicity profile and pharmacokinetic study of a phase I low-dose schedule-dependent radiosensitizing paclitaxel chemoradiation regimen for inoperable non-small-cell lung cancer (Q33378092) (← links)
- Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer (Q33385378) (← links)
- Phase II study of nedaplatin and irinotecan with concurrent thoracic radiotherapy in patients with locally advanced non-small-cell lung cancer (Q33392253) (← links)
- Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). (Q33401383) (← links)
- Phase I study of celecoxib with concurrent irinotecan, Cisplatin, and radiation therapy for patients with unresectable locally advanced non-small cell lung cancer (Q33401530) (← links)
- High-dose 3-dimensional conformal radiotherapy with concomitant vinorelbine plus carboplatin in patients with non-small cell lung cancer: A feasibility study (Q33402602) (← links)
- Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer. (Q33412557) (← links)
- Phase II study of concurrent chemoradiotherapy with carboplatin and vinorelbine for locally advanced non-small-cell lung cancer (Q33414911) (← links)
- Thoracic Vertebral Body Irradiation Contributes to Acute Hematologic Toxicity During Chemoradiation Therapy for Non-Small Cell Lung Cancer. (Q33428648) (← links)
- Effect of normal lung definition on lung dosimetry and lung toxicity prediction in radiation therapy treatment planning (Q33637920) (← links)
- Surgical management of advanced non-small cell lung cancer. (Q33658215) (← links)
- Misjudgement of gefitinib efficacy in patients with central non-small-cell lung cancer due to obstructive atelectasis caused by stereotactic radiotherapy (Q33733807) (← links)
- Early body weight loss during concurrent chemo-radiotherapy for non-small cell lung cancer (Q33741097) (← links)
- The prognostic impact of supraclavicular lymph node in N3-IIIB stage non-small cell lung cancer patients treated with definitive concurrent chemo-radiotherapy (Q33829279) (← links)
- A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117 (Q33847603) (← links)
- Novel approaches to locally advanced unresectable non-small cell lung cancer (Q33902547) (← links)
- Analysis of clinical and dosimetric factors associated with severe acute radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent chemotherapy and intensity-modulated radiotherapy (Q33907268) (← links)
- Evidence based radiation oncology with existing technology (Q33922185) (← links)
- Locoregional tumor failure after definitive radiation for patients with stage III non-small cell lung cancer (Q34135928) (← links)
- Radiation-Guided Drug Delivery to Mouse Models of Lung Cancer (Q34204251) (← links)
- Self-assembled nanoscale coordination polymers with trigger release properties for effective anticancer therapy (Q34275000) (← links)
- Surface layer-preserving photodynamic therapy (SPPDT) in a subcutaneous mouse model of lung cancer (Q34323682) (← links)
- Sequential chemo-radiotherapy in non-small cell lung cancer (Q34384430) (← links)
- Concomitant radiochemotherapy of advanced non-small-cell lung cancer (Q34384438) (← links)
- Trends and perspectives in multimodality therapy of locoregionally advanced non-small cell lung cancer (Q34384453) (← links)
- Development of treatment strategies in locally advanced non-small cell lung cancer (take home messages). (Q34384459) (← links)
- Combined modality treatment with chemotherapy and radiation in locally advanced non-small cell lung cancer (Q34447507) (← links)
- The role of chemotherapy in early non-small-cell lung cancer management. (Q34461776) (← links)
- Novel approaches to the treatment of non-small cell lung cancer. (Q34498105) (← links)